{"groups":[{"description":"Dasatinib was administered orally at a dose of 140 mg once a day (QD) until disease progression, drug toxicity, withdrawal of consent, investigator or sponsor decision, pregnancy, or decision to do stem cell transplant.","id":"FG000","title":"Dasatinib 140 mg QD"},{"description":"Dasatinib was administered orally at a dose of 70 mg twice a day (BID) until disease progression, drug toxicity, withdrawal of consent, investigator or sponsor decision, pregnancy, or decision to do stem cell transplant.","id":"FG001","title":"Dasatinib 70 mg BID"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}],"type":"Death prior to starting treatment"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"SAE prior to starting treatment"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"306"},{"groupId":"FG001","numSubjects":"305"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"305"},{"groupId":"FG001","numSubjects":"304"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}],"type":"NOT COMPLETED"}],"title":"Randomized"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"23"},{"groupId":"FG001","numSubjects":"22"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"141"},{"groupId":"FG001","numSubjects":"122"}],"type":"Disease Progression"},{"reasons":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"9"}],"type":"Physician Decision"},{"reasons":[{"groupId":"FG000","numSubjects":"59"},{"groupId":"FG001","numSubjects":"58"}],"type":"Other"},{"reasons":[{"groupId":"FG000","numSubjects":"62"},{"groupId":"FG001","numSubjects":"80"}],"type":"Study Drug Toxicity"},{"reasons":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"13"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}],"type":"Unknown (case report form lost)"}],"milestones":[{"achievements":[{"comment":"1 participant randomized to QD but received BID in error. 304 represents actual QD treatment.","groupId":"FG000","numSubjects":"304"},{"comment":"1 participant randomized to QD but received BID in error. 305 represents actual BID treatment.","groupId":"FG001","numSubjects":"305"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"304"},{"groupId":"FG001","numSubjects":"305"}],"type":"NOT COMPLETED"}],"title":"Treated With Study Drug"}],"preAssignmentDetails":"638 participants were enrolled; 27 were not randomized due to: adverse event (1), death (5), other (5), poor/noncompliance (1), no longer met criteria (13), withdrew consent (2). A total of 611 were randomized to treatment; 609 were treated: 2 randomized but not treated due to death (1) and serious adverse event (1).","recruitmentDetails":"Study started June 2005; recruitment completed March 2006; study ended June 2013 (Year 7) when the study closed and all participants were off study treatment. Those participants who were resistant or intolerant to prior imatinib were enrolled."}